View Item 

Show simple item record

Prolonged remission in multiple relapsed MLL-rearranged infant B-ALL with inotuzumab ozogamicin
dc.contributor.authorLattupally, Akhila
dc.contributor.authorLorenzana, Adonis
dc.contributor.authorYanik, Gregory Anthony
dc.contributor.authorBell, Danielle
dc.date.accessioned2023-03-03T21:08:52Z
dc.date.available2024-05-03 16:08:51en
dc.date.available2023-03-03T21:08:52Z
dc.date.issued2023-04
dc.identifier.citationLattupally, Akhila; Lorenzana, Adonis; Yanik, Gregory Anthony; Bell, Danielle (2023). "Prolonged remission in multiple relapsed MLL-rearranged infant B-ALL with inotuzumab ozogamicin." Pediatric Blood & Cancer 70(4): n/a-n/a.
dc.identifier.issn1545-5009
dc.identifier.issn1545-5017
dc.identifier.urihttps://hdl.handle.net/2027.42/175894
dc.publisherWiley Periodicals, Inc.
dc.titleProlonged remission in multiple relapsed MLL-rearranged infant B-ALL with inotuzumab ozogamicin
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelPediatrics
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/175894/1/pbc30055_am.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/175894/2/pbc30055.pdf
dc.identifier.doi10.1002/pbc.30055
dc.identifier.sourcePediatric Blood & Cancer
dc.identifier.citedreferenceBhojwani D, Sposto R, Shah NN, et�al. Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. Leukemia. 2019; 33: 884 - 892.
dc.identifier.citedreferencePieters R, De Lorenzo P, Ancliffe P, et�al. Outcome of infants younger than 1 year with acute lymphoblastic leukemia treated with the interfant-06 protocol: results from an international phase III randomized study. J Clin Oncol. 2019; 37: 2246 - 2256.
dc.identifier.citedreferenceBrivio E, Chantrain CF, Gruber TA, et�al. Inotuzumab ozogamicin in infants and young children with relapsed or refractory acute lymphoblastic leukemia: a case series. Br J Haematol. 2021; 193: 1172 - 1177.
dc.identifier.citedreferenceDriessen EMC, De Lorenzo P, Campbell M, et�al. Outcome of relapsed infant acute lymphoblastic leukemia treated on the interfant-99 protocol. Leukemia. 2016; 30: 1184 - 1187.
dc.identifier.citedreferenceMcNeer JL, Rau RE, Gupta S, Maude SL, O’Brien MM. Cutting to the front of the line: immunotherapy for childhood acute lymphoblastic leukemia. Am Soc Clin Oncol Educ B. 2020; 40: e132 - e143.
dc.identifier.citedreferenceStock W, G�kbuget N, Brien SO, et�al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016; 375: 740 - 753.
dc.identifier.citedreferenceJabbour EJ, Deangelo DJ, Stelljes M, Stock W, Liedtke M. Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATE. Cancer. 2018; 124: 1722 - 1732.
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
pbc30055_am.pdf
Size:
451.0KB
Format:
PDF
View/Open
Name:
pbc30055.pdf
Size:
142.7KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.